322 related articles for article (PubMed ID: 34794737)
1. Re-classification of uterine cervical cancer cases treated with radical hysterectomy based on the 2018 FIGO staging system.
Osaku D; Komatsu H; Okawa M; Iida Y; Sato S; Oishi T; Harada T
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1054-1058. PubMed ID: 34794737
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: A single center retrospective study.
Zeng J; Qu P; Hu Y; Sun P; Qi J; Zhao G; Gao Y
Medicine (Baltimore); 2020 Apr; 99(16):e19714. PubMed ID: 32311956
[TBL] [Abstract][Full Text] [Related]
3. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
[TBL] [Abstract][Full Text] [Related]
4. Para-aortic lymph node involvement revisited in the light of the revised 2018 FIGO staging system for cervical cancer.
Ayhan A; Aslan K; Öz M; Tohma YA; Kuşçu E; Meydanli MM
Arch Gynecol Obstet; 2019 Sep; 300(3):675-682. PubMed ID: 31263988
[TBL] [Abstract][Full Text] [Related]
5. Locoregional spread and survival of stage IIA1 versus stage IIA2 cervical cancer.
Hongladaromp W; Tantipalakorn C; Charoenkwan K; Srisomboon J
Asian Pac J Cancer Prev; 2014; 15(2):887-90. PubMed ID: 24568513
[TBL] [Abstract][Full Text] [Related]
6. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
[TBL] [Abstract][Full Text] [Related]
7. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?
Ayhan A; Aslan K; Bulut AN; Akilli H; Öz M; Haberal A; Meydanli MM
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():209-214. PubMed ID: 31325847
[TBL] [Abstract][Full Text] [Related]
8. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors.
Yan DD; Tang Q; Chen JH; Tu YQ; Lv XJ
Cancer Manag Res; 2019; 11():5473-5480. PubMed ID: 31354353
[No Abstract] [Full Text] [Related]
10. The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC).
van Kol KGG; Ebisch RMF; van der Aa M; Wenzel HB; Piek JMJ; Bekkers RLM
Gynecol Oncol; 2023 Apr; 171():9-14. PubMed ID: 36804623
[TBL] [Abstract][Full Text] [Related]
11. Search for conditions to avoid parametrectomy during radical hysterectomy for cervical cancer.
Ito F; Sugiura A; Toyoda S; Itani Y; Iwai K; Yamada Y; Tanase Y; Kawaguchi R; Kobayashi H; Kita T
J Obstet Gynaecol Res; 2019 Jul; 45(7):1371-1375. PubMed ID: 31106933
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines.
Wright JD; Matsuo K; Huang Y; Tergas AI; Hou JY; Khoury-Collado F; St Clair CM; Ananth CV; Neugut AI; Hershman DL
Obstet Gynecol; 2019 Jul; 134(1):49-57. PubMed ID: 31188324
[TBL] [Abstract][Full Text] [Related]
13. A Single-Institution Radical Surgery Results in Stage IB2/IIA2 (Bulky) Cervical Cancer.
Khatib G; Küçükgöz Güleç Ü; Bariş Güzel A; Uygur B; Seydaoğlu G; Gümürdülü D; Vardar MA
Int J Gynecol Cancer; 2016 Oct; 26(8):1480-4. PubMed ID: 27465899
[TBL] [Abstract][Full Text] [Related]
14. [Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].
Wang W; Shang C; Huang J; Chen S; Shen H; Yao S
Zhonghua Fu Chan Ke Za Zhi; 2015 Dec; 50(12):894-901. PubMed ID: 26887872
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral lymphatic vessel density and clinicopathologic features of patients with early-stage cervical cancer after radical hysterectomy.
Zaganelli FL; Carvalho FM; Almeida BG; Bacchi CE; Goes JC; Calil MA; Baracat EC; Carvalho JP
Int J Gynecol Cancer; 2010 Oct; 20(7):1225-31. PubMed ID: 21135594
[TBL] [Abstract][Full Text] [Related]
16. Early cervical carcinoma: the natural history of lymph node involvement redefined on the basis of thorough parametrectomy and giant section study.
Benedetti-Panici P; Maneschi F; D'Andrea G; Cutillo G; Rabitti C; Congiu M; Coronetta F; Capelli A
Cancer; 2000 May; 88(10):2267-74. PubMed ID: 10820348
[TBL] [Abstract][Full Text] [Related]
17. Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation.
Kasamatsu T; Onda T; Sawada M; Kato T; Ikeda S
Gynecol Oncol; 2009 Jul; 114(1):69-74. PubMed ID: 19398126
[TBL] [Abstract][Full Text] [Related]
18. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
Rutledge TL; Kamelle SA; Tillmanns TD; Gould NS; Wright JD; Cohn DE; Herzog TJ; Rader JS; Gold MA; Johnson GA; Walker JL; Mannel RS; McMeekin DS
Gynecol Oncol; 2004 Oct; 95(1):70-6. PubMed ID: 15385112
[TBL] [Abstract][Full Text] [Related]
19. Can pelvic lymphadenectomy be omitted in stage IA2 to IIB uterine cervical cancer?
Togami S; Kamio M; Yanazume S; Yoshinaga M; Douchi T
Int J Gynecol Cancer; 2014 Jul; 24(6):1072-6. PubMed ID: 24905616
[TBL] [Abstract][Full Text] [Related]
20. Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients.
Tsuruga T; Fujimoto A; Kawana K; Mori M; Hasumi Y; Kino N; Tomio K; Miura S; Tanikawa M; Sone K; Miyamoto Y; Ikeda Y; Kojima S; Adachi K; Nagasaka K; Matsumoto Y; Arimoto T; Oda K; Nakagawa S; Horie K; Yasugi T; Yokota H; Osuga Y; Fujii T
Int J Clin Oncol; 2016 Apr; 21(2):359-366. PubMed ID: 26438230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
